Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer Survivors
Advances in pediatric cancer therapies have dramatically improved the likelihood of survival. As survivors are aging, however, we are now understanding that treatment carries a significant risk of cardiovascular toxicity, which can develop immediately, or even many years after completing therapy. An...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Hearts |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-3846/2/1/5 |
| _version_ | 1797411239692861440 |
|---|---|
| author | Valerie Curren Niti Dham Christopher Spurney |
| author_facet | Valerie Curren Niti Dham Christopher Spurney |
| author_sort | Valerie Curren |
| collection | DOAJ |
| description | Advances in pediatric cancer therapies have dramatically improved the likelihood of survival. As survivors are aging, however, we are now understanding that treatment carries a significant risk of cardiovascular toxicity, which can develop immediately, or even many years after completing therapy. Anthracycline derivates are some of the most commonly used agents in pediatric oncology treatment protocols, which have a dose-dependent correlation with the development of cardiac toxicity. As we learn more about the mechanisms of toxicity, we are developing prevention strategies, including improvements in surveillance, to improve early diagnosis of heart disease. Current survivorship surveillance protocols often include screening echocardiograms to evaluate systolic function by measuring the ejection fraction or fractional shortening. However, these measurements alone are not enough to capture early myocardial changes. The use of additional imaging biomarkers, serum biomarkers, electrocardiograms, as well as cholesterol and blood pressure screening, are key to the early detection of cardiomyopathy and cardiovascular disease. Medical treatment strategies are the same as those used for heart failure from other causes, but earlier recognition and implementation can lead to improved long term outcomes. |
| first_indexed | 2024-03-09T04:42:09Z |
| format | Article |
| id | doaj.art-aa116297e2a9432f966b4999539e7a0b |
| institution | Directory Open Access Journal |
| issn | 2673-3846 |
| language | English |
| last_indexed | 2024-03-09T04:42:09Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Hearts |
| spelling | doaj.art-aa116297e2a9432f966b4999539e7a0b2023-12-03T13:19:16ZengMDPI AGHearts2673-38462021-01-0121456010.3390/hearts2010005Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer SurvivorsValerie Curren0Niti Dham1Christopher Spurney2Division of Pediatric Cardiology, Children’s National Hospital, 111 Michigan Ave NW, Washington, DC 20010, USADivision of Pediatric Cardiology, Children’s National Hospital, 111 Michigan Ave NW, Washington, DC 20010, USADivision of Pediatric Cardiology, Children’s National Hospital, 111 Michigan Ave NW, Washington, DC 20010, USAAdvances in pediatric cancer therapies have dramatically improved the likelihood of survival. As survivors are aging, however, we are now understanding that treatment carries a significant risk of cardiovascular toxicity, which can develop immediately, or even many years after completing therapy. Anthracycline derivates are some of the most commonly used agents in pediatric oncology treatment protocols, which have a dose-dependent correlation with the development of cardiac toxicity. As we learn more about the mechanisms of toxicity, we are developing prevention strategies, including improvements in surveillance, to improve early diagnosis of heart disease. Current survivorship surveillance protocols often include screening echocardiograms to evaluate systolic function by measuring the ejection fraction or fractional shortening. However, these measurements alone are not enough to capture early myocardial changes. The use of additional imaging biomarkers, serum biomarkers, electrocardiograms, as well as cholesterol and blood pressure screening, are key to the early detection of cardiomyopathy and cardiovascular disease. Medical treatment strategies are the same as those used for heart failure from other causes, but earlier recognition and implementation can lead to improved long term outcomes.https://www.mdpi.com/2673-3846/2/1/5cardio-oncologycardiomyopathypediatricanthracycline toxicitychemotherapysurveillance |
| spellingShingle | Valerie Curren Niti Dham Christopher Spurney Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer Survivors Hearts cardio-oncology cardiomyopathy pediatric anthracycline toxicity chemotherapy surveillance |
| title | Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer Survivors |
| title_full | Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer Survivors |
| title_fullStr | Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer Survivors |
| title_full_unstemmed | Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer Survivors |
| title_short | Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer Survivors |
| title_sort | diagnosis prevention treatment and surveillance of anthracycline induced cardiovascular toxicity in pediatric cancer survivors |
| topic | cardio-oncology cardiomyopathy pediatric anthracycline toxicity chemotherapy surveillance |
| url | https://www.mdpi.com/2673-3846/2/1/5 |
| work_keys_str_mv | AT valeriecurren diagnosispreventiontreatmentandsurveillanceofanthracyclineinducedcardiovasculartoxicityinpediatriccancersurvivors AT nitidham diagnosispreventiontreatmentandsurveillanceofanthracyclineinducedcardiovasculartoxicityinpediatriccancersurvivors AT christopherspurney diagnosispreventiontreatmentandsurveillanceofanthracyclineinducedcardiovasculartoxicityinpediatriccancersurvivors |